These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27922598)

  • 1. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
    Charmsaz S; Al-Ejeh F; Yeadon TM; Miller KJ; Smith FM; Stringer BW; Moore AS; Lee FT; Cooper LT; Stylianou C; Yarranton GT; Woronicz J; Scott AM; Lackmann M; Boyd AW
    Leukemia; 2017 Aug; 31(8):1779-1787. PubMed ID: 27922598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.
    Vearing C; Lee FT; Wimmer-Kleikamp S; Spirkoska V; To C; Stylianou C; Spanevello M; Brechbiel M; Boyd AW; Scott AM; Lackmann M
    Cancer Res; 2005 Aug; 65(15):6745-54. PubMed ID: 16061656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
    La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
    Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
    Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M
    Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high affinity recombinant antibody to the human EphA3 receptor with enhanced ADCC activity.
    Tomasevic N; Luehrsen K; Baer M; Palath V; Martinez D; Williams J; Yi C; Sujatha-Bhaskar S; Lanke R; Leung J; Ching W; Lee A; Bai L; Yarranton G; Bebbington C
    Growth Factors; 2014 Dec; 32(6):223-35. PubMed ID: 25413948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
    Uno S; Kinoshita Y; Azuma Y; Tsunenari T; Yoshimura Y; Iida S; Kikuchi Y; Yamada-Okabe H; Fukushima N
    Oncol Rep; 2007 May; 17(5):1189-94. PubMed ID: 17390064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
    Bieber MM; Twist CJ; Bhat NM; Teng NN
    Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
    Uckun FM; Qazi S; Dibirdik I; Myers DE
    Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
    Dijoseph JF; Dougher MM; Armellino DC; Evans DY; Damle NK
    Leukemia; 2007 Nov; 21(11):2240-5. PubMed ID: 17657218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
    London M; Gallo E
    Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.